医疗辅助技术(介入治疗）国家临床医学研究中心 ,苏州工业园区东方华夏心血管健康研究院 ,潘文志,冯沅,宋光远,刘先宝,张龙岩,李捷

• 1:复旦大学附属中山医院
• 2:四川大学华西医院
• 3:首都医科大学附属北京安贞医院
• 4:浙江大学医学院附属第二医院

摘要(Abstract)：

经导管主动脉瓣置换术（TAVR）在我国临床应用已逾15年，随着首批置入瓣膜进入耐久性衰减期，再次TAVR(Redo-TAVR)成为我国结构性心脏病领域亟待规范的重要临床场景。我国接受首次TAVR患者具有二叶式主动脉瓣比例高且瓣膜钙化重，风湿性病因和主动脉瓣反流常见等独特流行病学特征，且首次TAVR以自膨胀式瓣膜为主（占比93%），与欧美人群存在显著差异。本共识基于国际前沿研究数据及我国临床实践，系统阐述Redo-TAVR的适应证、禁忌证、术前评估、手术策略、临床效果、并发症防治、围手术期管理及远期随访，旨在规范我国Redo-TAVR临床操作，降低手术风险，改善患者长期预后，推动我国瓣膜性心脏病全生命周期管理体系建设。

关键词(KeyWords)： 经导管主动脉瓣置换术;再次经导管主动脉瓣置换术;生物瓣衰败;二叶式主动脉瓣;专家共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 医疗辅助技术(介入治疗）国家临床医学研究中心 ,苏州工业园区东方华夏心血管健康研究院 ,潘文志,冯沅,宋光远,刘先宝,张龙岩,李捷

参考文献(References)：

• [1]Otto CM,Nishimura RA,Bonow RO,et al.2020 ACC/AHA Guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].J Am Coll Cardiol,2021,77(4):450-500.DOI:10.1016/j.jacc.2020.11.035.
• [2]Praz F,Borger MA,Lanz J,et al.2025 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2025,46(44):463 5-4736.DOI:10.109 3/eurheartj/ehaf194.
• [3]国家放射与治疗临床医学研究中心,苏州工业园区东方华夏心血管健康研究院.经导管主动脉瓣置换术中国专家共识(2025版)[J].中国介入心脏病学杂志,2025,33(12):661-674.DOI:10.3969/j.issn.1004-8812.2025.12.001.
• [4] Vekstein AM,Wegermann ZK,Manandhar P,et al.Outcomesof transcatheter aortic valve replacement in low-risk patients in the United States:a report from the STS/ACC TVT registry[J].Circulation,2025,151(16):1134-1146.DOI:10.1161/CIRCULATIONAHA.124.071838.
• [5]Mehaffey JH,Jagadeesan V,Hayanga JW,et al.Trends of aortic valve replacement in patients 65 years and younger in the United States[J].Ann Thorac Surg,2026,122(1):67-73.DOI:10.1016/j.athoracsur.2026.01.031.
• [6] Mehaffey JH,Jagadeesan V,Bowdish M,et al.Young transcatheter aortic valve implantation:shifting risk and outcomes[J].Eur J Cardiothorac Surg,2026,68(2):ezag103.DOI:10.1093/ej cts/ezag103.
• [7]Sathananthan J,Lauck S,Polderman J,et al.Ten year followup of high-risk patients treated during the early experience with transcatheter aortic valve replacement[J].Catheter Cardiovasc Interv,2021,97(3):E431-E437.DOI:10.1002/ccd.29124.
• [8]Ferrarotto L,ImmèS,Tamburino C,et al.Ten years of transcatheter aortic valve implantation in the NOTION study:the good and the bad[J].Eur Heart J Suppl,2025,27(Suppl 3):ⅲ153-ⅲ155.DOI:10.10 9 3/eurheartj supp/suaf039.
• [9]Tang GHL,Zaid S,Kleiman NS,et al.Explant vs RedoTAVR after transcatheter valve failure:mid-term outcomes from the EXPLANTORREDO-TAVR international registry[J].JACC Cardiovasc Interv,2023,16(8):927-941.DOI:10.1016/j.jcin.2023.01.376.
• [10]Zhou D,Pan W,Wang J,et al.VitaFlow~(TM)transcatheter valve system in the treatment of severe aortic stenosis:oneyear results of a multicenter study[J].Catheter Cardiovasc Interv,2020,95(2):332-3 38.DOI:10.1002/ccd.28226.
• [11]苏州工业园区东方华夏心血管健康研究院国家放射与治疗临床医学研究中心心脏瓣膜病介入中心专家组.心脏瓣膜病介入中心年度报告(2024)[J].中国介入心脏病学杂志,2025,33(11):614-619.DOI:10.3969/j.issn.1004-8812.2025.11.002.
• [12]Arnold SV,Manandhar P,Vemulapalli S,et al.Trends in transcatheter aortic valve replacement outcomes:insights from the STS/ACC TVT registry[J].JAMA Cardiol,2024,9(12):1115-1123.DOI:10.1001/j amacardio.2024,3453.
• [13]Yang Y,Wang Z,Chen Z,et al.Current status and etiology of valvular heart disease in China:a population-based survey[J].BMC Cardiovasc Disord,2021,21(1):339.DOI:10.1186/s12872-021-02154-8.
• [14]Jilaihawi H,Wu Y,Yang Y,et al.Morphological characteristics of severe aortic stenosis in China:imaging corelab observations from the first Chinese transcatheter aortic valve trial[J].Catheter Cardiovasc Interv,2015,85 Suppl 1:752-761.DOI:10.1002/ccd.25863.
• [15]Xu H,Liu Q,Cao K,et al.Distribution,characteristics,and management of older patients with valvular heart disease in China:China-DVD study[J].JACC Asia,2022,2(3):354-365.DOI:10.1016/j.jacasi.2021.11.013.
• [16]Hutt E,Mehra N,Desai MY.Valve-in-valve transcatheter aortic valve replacement versus redo aortic valve replacement:which procedure for which patient?[J].Expert Rev Cardiovasc Ther,2022,20(12):911-918.DOI:10.1080/14779072.2022.2153118.
• [17] Lee GS,Tang G,Zaid S,et al.The current state of redo transcatheter aortic valve replacement(TAVR)and limitations:why TAVR explant is important as the valve reintervention strategy[J].Ann Cardiothorac Surg,2025,14(2):98-111.DOI:10.21037/acs-2024-etavr-0149.
• [18]Landes U,Webb JG,De Backer O,et al.Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction[J].J Am Coll Cardiol,2020,75(16):1882-1893.DOI:10.1016/j.jacc.2020.02.051.
• [19]Bapat VN,Zaid S,Fukuhara S,et al.Surgical explantation after TAVR failure:mid-term outcomes from the EXPLANT-TAVR internatio nal registry[J].JACC Cardiovasc Interv,2021,14(18):1978-1991.DOI:10.1016/j.jcin.2021.07.015.
• [20]Fukuhara S,Brescia AA,Shiomi S,et al.Surgical explantation of transcatheter aortic bioprostheses:results and clinical implications[J].J Thorac Cardiovasc Surg,2021,162(2):539-547.e1.DOI:10.1016/j.jtcvs.2019.11.139.
• [21]Hawkins RB,Hamilton BCS,Sukul D,et al.Increased risk of surgical aortic valve replacement after prior transcatheter vs surgical aortic valve replacement with concomitant valve disease[J].Ann Thorac Surg,2025,120(4):722-728.DOI:10.1016/j.athoracsur.2025.01.005.
• [22]Okada A,Zaid S,Fukui M,et al.Risk of coronary obstruction in Redo-transcatheter aortic valve replacement between bicuspid and tricuspid aortic valves[J].JACC Cardiovasc Interv,2025,18(9):1174-1185.DOI:10.1016/j.jcin.2025.02.016.
• [23]Medranda GA,Soria Jimenez CE,Torguson R,et al.Lifetime management of patients with symptomatic severe aortic stenosis:a computed tomography simulation study[J].Euro Intervention,2022,18(5):e407-e416.DOI:10.4244/EIJ-D-21-01091.
• [24]Miyawaki N,Ishizu K,Shirai S,et al.Assessing potential risks of future redo transcatheter aortic valve replacement in Asian patients[J].JACC Asia,2024,4(1):25-39.DOI:10.1016/j.jacasi.2023.09.004.
• [25]Kitamura M,Wilde J,Dumpies O,et al.Risk assessment of coronary obstruction during transcatheter aortic valve replacement:insights from post-BASILICA computed tomography[J].JACC Cardiovasc Interv,2022,15(5):496-507.DOI:10.1016/j.jcin.2022.01.003.
• [26]Windecker S,Tomii D.Planning for the future:CTbased insights into Redo-TAVR and lifetime aortic valve care[J].JACC Cardiovasc Interv,2025,18(9):1186-1189.DOI:10.1016/j.jcin.2025.04.005.
• [27]Ochiai T,Oakley L,Sekhon N,et al.Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement[J].JACC Cardiovasc Interv,2020,13(22):2617-2627.DOI:10.1016/j.jcin.2020.09.022.
• [28]Higuchi R,Otaki Y,Kanisawa M,et al.Risk of sinus sequestration during redo transcatheter aortic valve implantation:the prevalence,predictors,and risk stratification[J].Am J Cardiol,2024,211:1-8.DOI:10.1016/j.amjcard.2023.10.05 8.
• [29]Landes U,Richter I,Danenberg H,et al.Outcomes of redo transcatheter aortic valve replacement according to the initial and subsequent valve type[J].JACC Cardiovasc Interv,2022,15(15):1543-15 54.DOI:10.1016/j.jcin.2022.05.016.
• [30]Grubb KJ,Shekiladze N,Spencer J,et al.Feasibility of Redo-TAVI in self-expanding Evolut valves:a CT analysis from the Evolut low risk trial substudy[J].Euro Intervention,2023,19(4):e3 30-e33 9.DOI:10.4244/EIJ-D-22-01125.
• [31]Travieso A,Zaid S,N??rgaard BL,et al.Impact of valve sizing and positioning on expansion and hemodynamics in Redo TAVR with SAPIEN 3[J]. JACC Cardiovasc Interv,2025,18(2):276-278.DOI:10.1016/j.jcin.2024.10.045.
• [32]Meier D,Akodad M,Landes U,et al.Coronary access following Redo TAVR:impact of THV design,implant technique,and cell misalignment[J].JACC Cardiovasc Interv,2022,15(15):1519-1531.DOI:10.1016/j.jcin.2022.05.005.
• [33]Meier D,Landes U,Sondergaard L,et al.Redo-TAVI with SAPIEN 3 in SAPIEN XT or SAPIEN 3-impact of pre-and post-dilatation on final THV expansion[J].EuroIntervention,2023,19(9):757-765.DOI:10.4244/EIJ-D-23-00308.
• [34]Tang GHL,Hooda A,Zaid S,et al.Outcomes and feasibility of redoTAVR after Sapien 3 Ultra TAVR in extremely-undersized versus nominally-sized annuli[J].Catheter Cardiovasc Interv,2022,99(6):1935-1944.DOI:10.1002/ccd.30146.
• [35]Akodad M,Sellers S,Landes U,et al.Balloon-expandable valve for treatment of Evolut valve failure:implications on neoskirt height and leaflet overhang[J].JACC Cardiovasc Interv,2022,15(4):36 8-3 77.DOI:10.1016/j.jcin.2021.12.021.
• [36] Akodad M,Meier D,Sellers S,et al.A bench study of balloonexpandable valves for the treatment of self-expanding valve failure[J].EuroIntervention,2023,19(1):93-102.DOI:10.4244/EIJ-D-22-00769.
• [37]Beneduce A,Khokhar AA,Curio J,et al.Chimney stenting for preventing coronary obstruction in redo-TAVI with balloonexpandable valves within self-expanding valves[J].EuroIntervention,2025,21(12):e692-e703.DOI:10.4244/EIJ-D-24-01018.
• [38]Khan JM,Dvir D,Greenbaum AB,et al.Transcatheter laceration of aortic leaflets to prevent coronary obstruction during transcatheter aortic valve replacement:concept to first-in-human[J].JACC Cardiovasc Interv,2018,11(7):677-689.DOI:10.1016/j.jcin.2018.01.247.
• [39]Khan JM,Greenbaum AB,B abaliaros VC,et al.BASILICA trial:one-year outcomes of transcatheter electrosurgical leaflet laceration to prevent TAVR coronary obstruction[J].Circ Cardiovasc Interv,2021,14(5):e010238.DOI:10.1161/CIRCINTERVENTIONS.120.01023 8.
• [40]Tafciu E,Pesarini G,Ribichini F.Ultrasound imaging integration to prevent coronary obstruction during valve-in-valve transcatheter aortic valve implantation[J].Catheter Cardiovasc Interv,2025,106(3):1657-1660.DOI:10.1002./ccd.31740.
• [41]Dvir D,TchétchéD,Leon MB,et al.Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction:the ShortCut study[J].Eur Heart J,2024,45(33):3031-3041.DOI:10.1093/eurheartj/ehae303.
• [42]Iskander M,Anwaruddin S,Pearson P,et al.Percutaneous transapical bioprosthetic leaflet modification facilitated transfemoral valvein-surgical bioprosthetic transcatheter aortic valve replacement:undermining iatrogenic coronary obstruction with radiofrequency needle(UNICORN)[J].Catheter Cardiovasc Interv,2025,106(3):1920-1925.DOI:10.1002/ccd.70037.
• [43]Wong CK,Eric Chan KY,Chan DT,et al.UNICORN for valve-in-valve transcatheter aortic valve replacement:UNICORN Hong Kong registry[J].JACC Asia,2026,6(1):52-63.DOI:10.1016/j.jacasi.2025.10.011.
• [44]Chen F,Xiong T,Li Y,et al.Risk of coronary obstruction during Redo-TAVR in patients with bicuspid versus tricuspid aortic valve stenosis[J].JACC Cardiovasc Interv,2022,15(7):712-724.DOI:10.1016/j.jcin.2022.01.282.
• [45] Reddy P,Rodriguez-Weisson FJ,Medranda GA,et al.Impact of calcified raphe on TAVR in bicuspid patients:predicting Redo-TAVR feasibility and virtual planning implications[J].Circ Cardiovasc Interv,2025,18(6):e014802.DOI:10.1161/CIRCINTERVENTIONS.124.014 802.
• [46]Dvir D,Webb JG,Bleiziffer S,et al.Valve-in valve international data registry investigators.Transcatheter aortic valve implantation in failed bioprosthetic surgical valves[J].JAMA,2014,312(2):162-170.DOI:10.1001/jama.2014.7246.
• [47]Makkar RR,Kapadia S,Chakravarty T,et al.Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves:a registry study[J].Lancet,2023,402(10412):1529-1540.DOI:10.1016/S0140-6736(2 3)01636-7.
• [48] Percy ED,Harloff MT,Hirji S,et al.Nationally representative repeat transcatheter aortic valve replacement outcomes:report from the centers for medicare and medicaid services[J].JACC Cardiovasc Interv,2021,14(15):1717-1726.DOI:10.1016/j.jcin.2021.06.011.